Amarin Corporation plc (AMRN) NASDAQ
14.36
-0.13(-0.90%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
14.36
-0.13(-0.90%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
275
First IPO Date
April 01, 1993
| Name | Title | Pay | Year Born |
| Aaron D. Berg | Chief Executive Officer, President & Director | 1.66M | 1963 |
| Peter Fishman | Senior Vice President & Chief Financial Officer | 750,989 | 1984 |
| Jonathan N. Provoost | Executive Vice President, Chief Legal & Compliance Officer and Secretary | 931,207 | 1970 |
| David Keenan | Executive Vice President & Chief Operating Officer | 1.19M | 1968 |
| Steven Ketchum | Executive Vice President, President of Research & Development and Chief Scientific Officer | 1.49M | 1965 |
| Eric Boothe | Senior Vice President of Corporate Development | 0 | N/A |
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.